Validose, a NYC-based precision medicine supply firm, raised $2M in Pre-Seed funding.
The spherical was led by Peter Bauer’s Household Workplace as a part of its Expertise for Humanity technique, 10XBeta, and Interstate Fusion Ventures. Angel buyers additionally participated.
The corporate intends to make use of the funds to finalize the event of its ophthalmic answer, a smart-dose eye-dropper, which can be launched in Q2 2025.
Led by CEO Paul McGrath, Validose offers a platform that makes use of an agile dose system, coupled with real-time information delivered to clinicians, to leverage a set of behavioral prompts that may drive affected person habits. The expertise is designed to assist numerous therapies, together with the ophthalmic smart-dose answer, in addition to extra type elements, together with a CNS-focused nasal spray system and tablet supply system. The platform additionally delivers goal, exact, and safe real-time adherence information whereas offering personalised behavioral assist to enhance affected person compliance.
The platform features a Dose Exoskeleton—a multi-sensor, adaptable attachment that data adherence metrics throughout numerous medicine varieties. The exoskeleton can be utilized with nasal spray, ophthalmic drops, and different therapeutic purposes, enabling exact monitoring and scalability throughout a number of drug varieties. Validose additionally offers a Affected person Portal, which gives personalised dose reminders, real-time messaging, and behavioral teaching, selling lively affected person compliance with motivational prompts to take care of engagement. A Clinician Dashboard offers trial coordinators with real-time adherence insights, enabling them to make well timed interventions and optimize trial outcomes by means of safe, fast entry to affected person information.
FinSMEs
20/02/2025
